Enzychem Lifesciences Corporation
Enzychem Lifesciences Corporation operates in Diversified Metals & Mining.
Enzychem Lifesciences Corporation (183490) - Net Assets
Latest net assets as of June 2024: ₩181.70 Billion KRW
Based on the latest financial reports, Enzychem Lifesciences Corporation (183490) has net assets worth ₩181.70 Billion KRW as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩195.14 Billion) and total liabilities (₩13.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩181.70 Billion |
| % of Total Assets | 93.11% |
| Annual Growth Rate | 32.64% |
| 5-Year Change | 162.86% |
| 10-Year Change | N/A |
| Growth Volatility | 69.89 |
Enzychem Lifesciences Corporation - Net Assets Trend (2016–2023)
This chart illustrates how Enzychem Lifesciences Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enzychem Lifesciences Corporation (2016–2023)
The table below shows the annual net assets of Enzychem Lifesciences Corporation from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | ₩194.63 Billion | -3.53% |
| 2022-12-31 | ₩201.74 Billion | +170.21% |
| 2021-12-31 | ₩74.66 Billion | +3.01% |
| 2020-12-31 | ₩72.48 Billion | -2.10% |
| 2019-12-31 | ₩74.04 Billion | +25.88% |
| 2018-12-31 | ₩58.82 Billion | +139.46% |
| 2017-12-31 | ₩24.56 Billion | -8.89% |
| 2016-12-31 | ₩26.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enzychem Lifesciences Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8213002637000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩41.91 Billion | 21.66% |
| Other Components | ₩151.61 Billion | 78.34% |
| Total Equity | ₩193.52 Billion | 100.00% |
Enzychem Lifesciences Corporation Competitors by Market Cap
The table below lists competitors of Enzychem Lifesciences Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NWS HLDGS
BE:NWS
|
$7.37K |
|
Energent AG
MU:EM6
|
$7.37K |
|
LUNDIN PETROL - Dusseldorf Stock Exchang
DU:LYV
|
$7.37K |
|
REATO GROUP AB
F:D5LA
|
$7.38K |
|
MagForce AG
PINK:MGFRF
|
$7.37K |
|
RepliCel Life Sciences Inc
PINK:REPCF
|
$7.36K |
|
CPU Softwarehouse AG
F:CPU2
|
$7.36K |
|
112190
KO:112190
|
$7.35K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enzychem Lifesciences Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 201,744,080,190 to 193,515,936,800, a change of -8,228,143,390 (-4.1%).
- Net loss of 9,326,411,510 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-9.33 Billion | -4.82% |
| Other Changes | ₩1.10 Billion | +0.57% |
| Total Change | ₩- | -4.08% |
Book Value vs Market Value Analysis
This analysis compares Enzychem Lifesciences Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.31x to 0.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩3593.43 | ₩1115.00 | x |
| 2018-12-31 | ₩7610.12 | ₩1115.00 | x |
| 2019-12-31 | ₩9420.80 | ₩1115.00 | x |
| 2020-12-31 | ₩1157.81 | ₩1115.00 | x |
| 2021-12-31 | ₩1493.59 | ₩1115.00 | x |
| 2022-12-31 | ₩2393.51 | ₩1115.00 | x |
| 2023-12-31 | ₩2274.90 | ₩1115.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enzychem Lifesciences Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.27%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.09x
- Recent ROE (-4.82%) is above the historical average (-21.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -23.49% | -29.00% | 0.60x | 1.36x | ₩-9.03 Billion |
| 2017 | -23.07% | -21.68% | 0.71x | 1.50x | ₩-8.12 Billion |
| 2018 | -24.52% | -46.47% | 0.46x | 1.14x | ₩-20.30 Billion |
| 2019 | -22.80% | -53.64% | 0.37x | 1.15x | ₩-24.28 Billion |
| 2020 | -24.15% | -67.81% | 0.21x | 1.71x | ₩-24.76 Billion |
| 2021 | -37.32% | -121.28% | 0.17x | 1.78x | ₩-35.33 Billion |
| 2022 | -12.44% | -94.20% | 0.11x | 1.23x | ₩-45.27 Billion |
| 2023 | -4.82% | -12.27% | 0.36x | 1.09x | ₩-28.68 Billion |
Industry Comparison
This section compares Enzychem Lifesciences Corporation's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $101,285,795,421
- Average return on equity (ROE) among peers: -24.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enzychem Lifesciences Corporation (183490) | ₩181.70 Billion | -23.49% | 0.07x | $7.37K |
| Kukyoung G&M (006050) | $51.01 Billion | -2.56% | 0.37x | $8.37K |
| Kossen Co Ltd (009730) | $14.31 Billion | -212.62% | 2.32x | $3.71K |
| Haansoft (030520) | $549.72 Billion | 3.28% | 0.54x | $147.64K |
| BIT Computer (032850) | $54.93 Billion | 11.85% | 0.29x | $31.44K |
| Plumb Fast Co (035200) | $29.09 Billion | 11.02% | 0.35x | $21.53K |
| A-Frontier Co. Ltd. (036180) | $25.85 Billion | 16.56% | 0.27x | $3.84K |
| Infraware (041020) | $36.71 Billion | -39.68% | 0.21x | $29.45K |
| Kook Soon Dang Co. Ltd. (043650) | $215.68 Billion | -1.25% | 0.11x | $25.25K |
| Stcube (052020) | $38.70 Billion | -27.66% | 0.51x | $49.27K |
| Fourth-Link Inc. (056730) | $-3.13 Billion | 0.00% | 0.00x | $2.96K |